Galapagos NV
(NASDAQ: GLPG)
|
4:00 PM EDT, 04/17/24 | |||
---|---|---|---|---|
Last: $29.22 | Change: -0.27 | %Change: -0.92% | Volume: 192,831 |
Open: | $ 29.45 | Volume: | 192,831 | |
---|---|---|---|---|
High: | $ 29.50 | Yield(%) | 0.00 | |
Low: | $ 29.18 | P/E Ratio (ttm): | 8.41 | |
Dividend ($): | n/a | Market Cap ($): | 1.93B | |
EPS ($) | -2.32 | Shares Out: | 65.90M |
% Price Change (last 4 weeks): | -13.96 |
---|---|
% Price Change (last 13 weeks): | -24.50 |
% Price Change (last 26 weeks): | -14.96 |
% Price Change (last 52 weeks): | -22.60 |
% Price Change (year to date): | -28.12 |
Return on Equity (%): | -0.15 |
---|---|
Return on Assets (%): | -0.09 |
Return on Invested Capital (%): | -3.28 |
Gross Profit Margin (%): | 84.99 |
---|---|
Net Profit Margin (%): | -1.66 |
Operating Profit Margin (%): | -53.35 |
50-day Moving Average: | $34.65 |
---|---|
200-day Moving Average: | $37.22 |
Avg. Daily Vol. (last 50 days): | 129,734 |
Avg. Daily Vol. (last 200 days): | 141,081 |
52-wk high: | $45.21 |
52-wk low: | $29.18 |
Bid: | $28.99 |
Ask: | $29.08 |
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
|
Galapagos NV
Industriepark Mechelen Noord Generaal de Wittelaan L11 A3 Mechelen BU 2800 Phone: 32.1.534.29.00 Fax: n/a http://www.glpg.com |
Earnings (1year) ($): | -2.32 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | 8.41 |
Book Value ($): | 46.86 |
Cash Flow ($): | 4.06 |
Price/Earnings (x): | 8.41 |
---|---|
Price/Sales (x): | 10.33 |
Price/Book (x): | 0.87 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 9.52 |
---|---|
Current Ratio (x): | 9.71 |
LT Debt/Equity (x): | 0.18 |
Total Debt/Equity (x): | 0.34 |